154 related articles for article (PubMed ID: 18922109)
1. Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate.
Klar U; Hoffmann J; Giurescu M
Expert Opin Investig Drugs; 2008 Nov; 17(11):1735-48. PubMed ID: 18922109
[TBL] [Abstract][Full Text] [Related]
2. Sagopilone, a microtubule stabilizer for the potential treatment of cancer.
Galmarini CM
Curr Opin Investig Drugs; 2009 Dec; 10(12):1359-71. PubMed ID: 19943207
[TBL] [Abstract][Full Text] [Related]
3. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.
Hoffmann J; Vitale I; Buchmann B; Galluzzi L; Schwede W; Senovilla L; Skuballa W; Vivet S; Lichtner RB; Vicencio JM; Panaretakis T; Siemeister G; Lage H; Nanty L; Hammer S; Mittelstaedt K; Winsel S; Eschenbrenner J; Castedo M; Demarche C; Klar U; Kroemer G
Cancer Res; 2008 Jul; 68(13):5301-8. PubMed ID: 18593931
[TBL] [Abstract][Full Text] [Related]
4. Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.
Winsel S; Sommer A; Eschenbrenner J; Mittelstaedt K; Klar U; Hammer S; Hoffmann J
PLoS One; 2011 Apr; 6(4):e19273. PubMed ID: 21559393
[TBL] [Abstract][Full Text] [Related]
5. Epothilones as lead structures for new anticancer drugs--pharmacology, fermentation, and structure-activity-relationships.
Altmann KH; Memmert K
Prog Drug Res; 2008; 66():273, 275-334. PubMed ID: 18416309
[TBL] [Abstract][Full Text] [Related]
6. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
7. Selected hybrid natural products as tubulin modulators.
Dasari B; Jimmidi R; Arya P
Eur J Med Chem; 2015 Apr; 94():497-508. PubMed ID: 25455639
[TBL] [Abstract][Full Text] [Related]
8. Diversity through semisynthesis: the chemistry and biological activity of semisynthetic epothilone derivatives.
Altmann KH; Gaugaz FZ; Schiess R
Mol Divers; 2011 May; 15(2):383-99. PubMed ID: 21197573
[TBL] [Abstract][Full Text] [Related]
9. Synthesis & antitumor activity of epothilones B and D and their analogs.
Cheng H; Huang G
Future Med Chem; 2018 Jun; 10(12):1483-1496. PubMed ID: 29788770
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of 12-aza-epothilones (azathilones)--"non-natural" natural products with potent anticancer activity.
Feyen F; Gertsch J; Wartmann M; Altmann KH
Angew Chem Int Ed Engl; 2006 Sep; 45(35):5880-5. PubMed ID: 16871640
[No Abstract] [Full Text] [Related]
11. The epothilones: how pharmacology relates to clinical utility.
Michaud LB
Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
[TBL] [Abstract][Full Text] [Related]
12. Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization.
Feyen F; Cachoux F; Gertsch J; Wartmann M; Altmann KH
Acc Chem Res; 2008 Jan; 41(1):21-31. PubMed ID: 18159935
[TBL] [Abstract][Full Text] [Related]
13. Epothilone analogues with benzimidazole and quinoline side chains: chemical synthesis, antiproliferative activity, and interactions with tubulin.
Dietrich SA; Lindauer R; Stierlin C; Gertsch J; Matesanz R; Notararigo S; Díaz JF; Altmann KH
Chemistry; 2009 Oct; 15(39):10144-57. PubMed ID: 19697384
[TBL] [Abstract][Full Text] [Related]
14. The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo.
Strube A; Suominen MI; Rissanen JP; Mumberg D; Klar U; Halleen JM; Käkönen SM
Osteoporos Int; 2011 Nov; 22(11):2887-93. PubMed ID: 21104229
[TBL] [Abstract][Full Text] [Related]
15. Epothilone B and its analogs - a new family of anticancer agents.
Altmann KH
Mini Rev Med Chem; 2003 Mar; 3(2):149-58. PubMed ID: 12570848
[TBL] [Abstract][Full Text] [Related]
16. The biology and medicinal chemistry of epothilones.
Wartmann M; Altmann KH
Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):123-48. PubMed ID: 12678754
[TBL] [Abstract][Full Text] [Related]
17. Natural products as leads for anticancer drug discovery: discovery of new chemotypes of microtubule stabilizers through reengineering of the epothilone scaffold.
Altmann KH; Cachoux F; Feyen F; Gertsch J; Kuzniewski CN; Wartmann M
Chimia (Aarau); 2010; 64(1-2):8-13. PubMed ID: 21137676
[TBL] [Abstract][Full Text] [Related]
18. Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial.
Arnold D; Voigt W; Kiewe P; Behrmann C; Lindemann S; Reif S; Wiesinger H; Giurescu M; Thiel E; Schmoll HJ
Br J Cancer; 2009 Oct; 101(8):1241-7. PubMed ID: 19773753
[TBL] [Abstract][Full Text] [Related]
19. Novel drugs targeting microtubules: the role of epothilones.
Ferrandina G; Mariani M; Andreoli M; Shahabi S; Scambia G; Ferlini C
Curr Pharm Des; 2012; 18(19):2793-803. PubMed ID: 22390763
[TBL] [Abstract][Full Text] [Related]
20. Recent developments in the chemical biology of epothilones.
Altmann KH
Curr Pharm Des; 2005; 11(13):1595-613. PubMed ID: 15892665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
